Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Investing Activities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Cash from Investing Activities data on record, last reported at $55.4 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 130.49% year-over-year to $55.4 million; the TTM value through Dec 2025 reached $209.1 million, up 172.06%, while the annual FY2025 figure was $209.1 million, 172.06% up from the prior year.
  • Cash from Investing Activities reached $55.4 million in Q4 2025 per CLDX's latest filing, down from $60.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $60.8 million in Q3 2025 and bottomed at -$315.2 million in Q1 2024.
  • Average Cash from Investing Activities over 5 years is -$15.7 million, with a median of $23.6 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: surged 406.45% in 2023, then plummeted 4114.0% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$18.9 million in 2021, then skyrocketed by 264.76% to $31.2 million in 2022, then crashed by 648.36% to -$171.2 million in 2023, then skyrocketed by 114.05% to $24.0 million in 2024, then skyrocketed by 130.49% to $55.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $55.4 million in Q4 2025, $60.8 million in Q3 2025, and $49.8 million in Q2 2025.